| Literature DB >> 15823702 |
M R Namazi1, J Soma.
Abstract
Oxidative stress and inflammatory cytokines such as monocyte chemoattractant protein 1 (MCP-1), TGF-beta, and IL-2 are supposed to play crucial roles in the pathogenesis of insulin resistance (IR). Tranilast is an anti-allergic drug which exerts anti-inflammatory and anti-angiogenesis effects through inhibition of expression of MCP-1, TGF-beta, and antigen-induced IL-2 lymphocyte responsiveness. It also possesses a certain antioxidant activity. Considering the above facts and in view of its safety, tranilast may prove invaluable in the treatment of IR.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15823702 DOI： 10.1016/j.mehy.2003.11.047
Source DB: PubMed Journal: Med Hypotheses ISSN： 0306-9877 Impact factor: 1.538